Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
Y-mAbs Therapeutics (NASDAQ: YMAB) has announced a virtual Radiopharmaceutical R&D update scheduled for May 28, 2025, at 8:00 a.m. ET. The 90-minute presentation will cover several key areas including:
- Part A clinical data from the ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), featuring pharmacokinetic and dosimetry data
- Updates on nonclinical optimization studies for the GD2-SADA asset and clinical implementation plans
- The company's Radiopharmaceutical pipeline strategy, including new planned target programs and timelines
The event will be accessible via webcast on Y-mAbs' Investor Relations website and will remain archived for at least 30 days.
Y-mAbs Therapeutics (NASDAQ: YMAB) ha annunciato un aggiornamento virtuale sulla Ricerca e Sviluppo in Radiopharmaceutica, previsto per il 28 maggio 2025 alle 8:00 ET. La presentazione di 90 minuti tratterà diverse aree chiave, tra cui:
- Dati clinici della Parte A del trial di Fase 1 in corso GD2-SADA (Trial 1001), con dati farmacocinetici e di dosimetria
- Aggiornamenti sugli studi di ottimizzazione non clinici per l'asset GD2-SADA e piani di implementazione clinica
- La strategia della pipeline Radiopharmaceutica dell'azienda, inclusi nuovi programmi target pianificati e relative tempistiche
L'evento sarà accessibile via webcast sul sito web delle Relazioni con gli Investitori di Y-mAbs e resterà archiviato per almeno 30 giorni.
Y-mAbs Therapeutics (NASDAQ: YMAB) ha anunciado una actualización virtual sobre I+D en Radiofármacos programada para el 28 de mayo de 2025 a las 8:00 a.m. ET. La presentación de 90 minutos cubrirá varias áreas clave, incluyendo:
- Datos clínicos de la Parte A del ensayo de Fase 1 en curso GD2-SADA (Ensayo 1001), con datos farmacocinéticos y de dosimetría
- Actualizaciones sobre estudios de optimización no clínica para el activo GD2-SADA y planes de implementación clínica
- Estrategia de la cartera de Radiofármacos de la compañía, incluyendo nuevos programas objetivo planificados y sus cronogramas
El evento será accesible vía webcast en el sitio web de Relaciones con Inversores de Y-mAbs y permanecerá archivado por al menos 30 días.
Y-mAbs Therapeutics (NASDAQ: YMAB)가 2025년 5월 28일 오전 8시 ET에 예정된 가상 방사성 의약품 연구개발 업데이트를 발표했습니다. 90분간 진행되는 이번 발표에서는 다음과 같은 주요 내용을 다룰 예정입니다:
- 진행 중인 1상 GD2-SADA 임상시험(시험 1001)의 파트 A 임상 데이터, 약동학 및 선량 측정 데이터 포함
- GD2-SADA 자산에 대한 비임상 최적화 연구 업데이트 및 임상 적용 계획
- 회사의 방사성 의약품 파이프라인 전략, 신규 목표 프로그램 및 일정 포함
이 행사는 Y-mAbs 투자자 관계 웹사이트를 통해 웹캐스트로 시청 가능하며 최소 30일간 아카이브됩니다.
Y-mAbs Therapeutics (NASDAQ : YMAB) a annoncé une mise à jour virtuelle sur la R&D en radiopharmaceutique prévue pour le 28 mai 2025 à 8h00 ET. La présentation de 90 minutes couvrira plusieurs domaines clés, notamment :
- Données cliniques de la Partie A de l'essai de Phase 1 en cours GD2-SADA (Essai 1001), incluant des données pharmacocinétiques et de dosimétrie
- Mises à jour sur les études d'optimisation non cliniques pour l'actif GD2-SADA et les plans de mise en œuvre clinique
- La stratégie de la pipeline radiopharmaceutique de la société, comprenant de nouveaux programmes cibles prévus et leurs calendriers
L'événement sera accessible via webcast sur le site Relations Investisseurs de Y-mAbs et restera archivé pendant au moins 30 jours.
Y-mAbs Therapeutics (NASDAQ: YMAB) hat ein virtuelles Update zur Radiopharmazeutischen Forschung und Entwicklung angekündigt, das für den 28. Mai 2025 um 8:00 Uhr ET geplant ist. Die 90-minütige Präsentation wird mehrere wichtige Bereiche abdecken, darunter:
- Klinische Daten aus Teil A der laufenden Phase-1-Studie GD2-SADA (Studie 1001), einschließlich pharmakokinetischer und Dosimetrie-Daten
- Updates zu nichtklinischen Optimierungsstudien für das GD2-SADA-Asset und klinische Umsetzungspläne
- Die Radiopharmazeutische Pipeline-Strategie des Unternehmens, einschließlich neuer geplanter Zielprogramme und Zeitpläne
Die Veranstaltung wird per Webcast auf der Investor-Relations-Website von Y-mAbs zugänglich sein und mindestens 30 Tage archiviert bleiben.
- None.
- None.
PRINCETON, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will hold a virtual Radiopharmaceutical R&D update at 8:00 a.m. ET on Wednesday, May 28, 2025.
During the virtual Radiopharmaceutical R&D update, Y-mAbs will discuss: Part A clinical data from the Company’s ongoing Phase 1 GD2-SADA clinical trial (Trial 1001), including pharmacokinetic and dosimetry data; updates around the Company's nonclinical optimization studies for the GD2-SADA asset and plans for clinical implementation; and the Company’s Radiopharmaceutical pipeline strategy, including new planned target programs and anticipated timelines.
The duration of the virtual Radiopharmaceutical R&D update is expected to be 90 minutes. A live audio webcast of the call will be available on the Investor Relations section of the Company’s website at https://ir.ymabs.com/events-and-presentations/events. The webcast will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2025 and beyond. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2025, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact: Courtney Dugan VP, Head of Investor Relations cdu@ymabs.com
FAQ
When is Y-mAbs (YMAB) hosting its Radiopharmaceutical R&D update in 2025?
What topics will be covered in Y-mAbs' (YMAB) May 2025 R&D update?
How long will Y-mAbs' (YMAB) May 2025 Radiopharmaceutical R&D presentation last?
Where can investors access Y-mAbs' (YMAB) May 2025 R&D presentation?
